Trial Profile
Phase 1 Trial of a Monoclonal Antibody to OX40 in Patients With Advanced Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs MEDI 6469 (Primary) ; Keyhole limpet haemocyanin; Tetanus vaccine
- Indications Cancer; Lymphoma
- Focus Adverse reactions
- 13 Jun 2017 Status changed from active, no longer recruiting to completed.
- 26 Sep 2016 Planned End Date changed from 1 Jan 2015 to 1 Jan 2017.
- 27 Jul 2012 New trial record